Researcher
Cynthia Ma, MD, PhD, Washington University, St. Louis, MO
Study Review
The purpose of this study was to see whether neratinib is effective in treating HER2-negative metastatic tumors that have this specific HER2 mutation.
The initial Call to Action for this study was on 3/19/2014 and the researchers closed enrollment on 3/24/2020. The Love Research Army provided them with 74 participants who were interested in enrolling in the study.
Resulting Publications:
